

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
**WO 2005/092384 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 45/06**,  
31/517, 33/24, 31/282

Robert [GB/GB]; AstraZeneca R & D Alderley, Alderley  
Park, Macclesfield Cheshire SK10 4TG (GB).

(21) International Application Number:  
PCT/GB2005/001079

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-SE-151 85 Soderatlje (SE).

(22) International Filing Date: 22 March 2005 (22.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0406450.7 23 March 2004 (23.03.2004) GB  
0407755.8 6 April 2004 (06.04.2004) GB

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,  
BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN,  
CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,  
FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR,  
HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MC, MD, MK, ML, MN, MR, MW,  
MX, MZ, NA, NE, NI, NL, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SI, SK only*): **ASTRAZENECA  
AB** [SE/SE]; S-SE-151 85 Sodertalje (SE).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIM-  
ITED** [GB/GB]; 15 Stanhope Gate, London Greater Lon-  
don W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **WEDGE, Stephen**

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION THERAPY

(57) Abstract: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reduc-  
ing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method  
for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in  
combination with a platinum anti-tumour agent; to a pharmaceutical composition comprising AZD2171 and a platinum anti-tumour  
agent; to a combination product comprising AZD2171 and a platinum anti-tumour agent for use in a method of treatment of a human  
or animal body by therapy; to a kit comprising AZD2171 and a platinum anti-tumour agent; to the use of AZD2171 and a platinum  
anti-tumour agent in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability  
reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.



WO 2005/092384 A2